Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record.

Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma

Open access
Polson, Andrew G., Yu, Shang-Fan, Elkins, Kristi, Zheng, Bing, Clark, Suzanna, Ingle, Gladys S., Slaga, Dionysos S., Giere, Lynne, Du, Changchun, Tan, Christine, Hongo, Jo-Anne, Gogineni, Alvin, Cole, Mary J., Vandlen, Richard, Stephan, Jean-Philippe, Young, Judy, Chang, Wesley, Scales, Suzie J., Ross, Sarajane, Eaton, Dan, Ebens, Allen · 2007 · Blood

Abstract

Targeting cytotoxic drugs to cancer cells using antibody–drug conjugates (ADCs), particularly those with stable linkers between the drug and the antibody, could be an effective cancer treatment with low toxicity. However, for stable-linker ADCs to be effective, they must be internalized and degraded, limiting potential targets to surface antigens that are trafficked to lysosomes. CD79a and CD79b comprise the hetrodimeric signaling component of the B-cell receptor, and are attractive targets for the use of ADCs because they are B-cell–specific, expressed in non-Hodgkin lymphomas (NHL), and are trafficked to a lysosomal-like compartment as part of antigen presentation. We show here that the stable-linker ADCs anti-CD79b-MCC-DM1 and anti-CD79b-MC-MMAF are capable of target-dependent killing of nonHodgkin lymphoma cell lines in vitro. Further, these 2 ADCs are equally effective as low doses in xenograft models of follicular, mantle cell, and Burkitt lymphomas, even though several of these cell lines express relatively low levels of CD79b in vivo. In addition, we demonstrate that anti-CD79b ADCs were more effective than anti-CD79a ADCs and that, as hypothesized, anti-CD79b antibodies downregulated surface B-cell receptor and were trafficked to the lysosomal-like major histocompatibility complex class II–positive compartment MIIC. These results suggest that anti-CD79b-MCC-DM1 and anti-CD79b-MC-MMAF are promising therapeutics for the treatment of NHL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2007-01-066704

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 173

Metadata

Authors
Polson, A. G., Yu, S.-F., Elkins, K., Zheng, B., Clark, S., Ingle, G. S., Slaga, D. S., Giere, L., Du, C., Tan, C., Hongo, J.-A., Gogineni, A., Cole, M. J., Vandlen, R., Stephan, J.-P., Young, J., Chang, W., Scales, S. J., Ross, S., Eaton, D., & Ebens, A.
Venue
Blood
Published
2007-07-15
Volume
110
Issue
2
Pages
616-623
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2069832110
Cited by
173
References
0
FWCI
7.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. https://app.cochat.ai/papers/10.1182/blood-2007-01-066704
The paper
Polson, A. G., Yu, S.-F., Elkins, K., Zheng, B., Clark, S., Ingle, G. S., Slaga, D. S., Giere, L., Du, C., Tan, C., Hongo, J.-A., Gogineni, A., Cole, M. J., Vandlen, R., Stephan, J.-P., Young, J., Chang, W., Scales, S. J., Ross, S., . . . Ebens, A. (2007). Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. https://doi.org/10.1182/blood-2007-01-066704

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.